Le Lézard17m
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...
Are America’s four main adversaries really in cahoots?
It’s clear that America’s principal global adversaries are increasingly cooperating, and policymakers and experts are ...